Inherited peripheral neuropathies

Neurologic Clinics

Volumn 31, Issue 2, 2013, Pages 597-619

  Saporta, Mario A ^a   Shy, Michael E ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Charcot Marie Tooth; Genetic testing; Inherited neuropathy

Indexed keywords

ASCORBIC ACID; CONNEXIN 32; GANGLIOSIDE; GAP JUNCTION PROTEIN; GLYCINE TRANSFER RNA LIGASE; HEAT SHOCK PROTEIN 27; MYELIN PROTEIN; ONAPRISTONE; PERIPHERAL MYELIN PROTEIN 22; SODIUM CHANNEL NAV1.7;

AUTOSOMAL DOMINANT INHERITANCE; CELL NUCLEUS; CHROMOSOME 17P; CLINICAL EVALUATION; CONGENITAL ANALGESIA; DAILY LIFE ACTIVITY; DEMYELINATING NEUROPATHY; DEMYELINATION; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DISORDERS OF PEROXISOMAL FUNCTIONS; DORSAL ROOT; ELECTROMYOGRAM; ELECTROPHYSIOLOGY; ENDOPLASMIC RETICULUM; FAMILIAL AMYLOID POLYNEUROPATHY; FAMILY HISTORY; GAP JUNCTION; GENE MUTATION; GENETIC COUNSELING; GENETIC DISORDER; GENETIC SCREENING; HEREDITARY MOTOR SENSORY NEUROPATHY; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INHERITANCE; LIPOPROTEIN DEFICIENCY; MOTONEURON; MOTOR NERVE CONDUCTION; MUSCLE ACTION POTENTIAL; MUSCLE CONTRACTURE; MYELIN SHEATH; NERVE BIOPSY; NERVE CELL; NERVE CONDUCTION; NERVE FIBER; NERVE FIBER DEGENERATION; NERVE FIBER TRANSPORT; NONHUMAN; OCCUPATIONAL THERAPY; ONCOGENE RAS; ONSET AGE; ORTHOPEDIC SURGERY; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NEUROPATHY; PHENOTYPE; PHYSIOTHERAPY; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SCHWANN CELL; SENSORY GANGLION; SENSORY NEUROPATHY; SPINAL MUSCULAR ATROPHY; TENDON TRANSFER; UNFOLDED PROTEIN RESPONSE; VOCAL CORD PARALYSIS;

ADULT; GENETIC HETEROGENEITY; GENETIC TESTING; HUMANS; MALE; MEMBRANE PROTEINS; MUTATION; NEURAL CONDUCTION; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 84877130911     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2013.01.009     Document Type: Review

References (113)

1. Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet 1974, 6(2):98-118.
2. Dyck P.J., Oviatt K.F., Lambert E.H. Intensive evaluation of referred unclassified neuropathies yields improved diagnosis. Ann Neurol 1981, 10:222-226.
3. Trapp B.D., Pfeiffer S.E., Anitei A., et al. Cell biology and myelin assembly. Myelin biology and disorders 2003, 29-56. Elsevier Academic Press, San Diego (CA), London. R.A. Lazzarini (Ed.).
4. Niemann A., Berger P., Suter U. Pathomechanisms of mutant proteins in Charcot-Marie-Tooth disease. Neuromolecular Med 2006, 8(1-2):217-242.
5. Li J. Hypothesis of double polarization. J Neurol Sci 2008, 275(1-2):33-36.
6. Bergoffen J., Scherer S.S., Wang S., et al. Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science 1993, 262(5142):2039-2042.
7. Krajewski K.M., Lewis R.A., Fuerst D.R., et al. Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain 2000, 123(7):1516-1527.
8. Colby J., Nicholson R., Dickson K.M., et al. PMP22 carrying the trembler or trembler-J mutation is intracellularly retained in myelinating Schwann cells. Neurobiol Dis 2000, 7:561-573.
9. Pennuto M., Tinelli E., Malaguti M., et al. Ablation of the UPR-mediator CHOP restores motor function and reduces demyelination in Charcot-Marie-Tooth 1BMice. Neuron 2008, 57:393-405.
10. Saporta M.A., Shy B.R., Patzko A., et al. MpzR98C arrests Schwann cell development in a mouse model of early-onset Charcot-Marie-Tooth disease type 1B. Brain 2012, 135(7):2032-2047.
11. Khajavi M., Shiga K., Wiszniewski W., et al. Oral curcumin mitigates the clinical and neuropathologic phenotype of the Trembler-J mouse: a potential therapy for inherited neuropathy. Am J Hum Genet 2007, 81:438-453.
12. Patzko A., Bai Y., Saporta M., et al. Curcumin derivatives promote Schwann cell differentiation and improve neuropathy in R98C CMT1B mice. Brain 2012, 135(12):3551-3566.
13. Harding A.E., Thomas P.K. Genetic aspects of hereditary motor and sensory neuropathy (types I and II). J Med Genet 1980, 17(5):329-336.
14. Harding A.E., Thomas P.K. The clinical features of hereditary motor and sensory neuropathy types I and II. Brain 1980, 103(2):259-280.
15. Thomas P.K., Harding A.E. Inherited neuropathies: the interface between molecular genetics and pathology. Brain Pathol 1993, 3(2):129-133.
16. Michels V.V., Dyck P.J. Mendelian inheritance and basis of classification of hereditary neuropathy with neuronal atrophy and degeneration. Peripheral neuropathy 1984, 1512-1524. W.B. Saunders Company, Philadelphia. 2nd edition. P. Dyck, P.K. Thomas, E.H. Lambert (Eds.).
17. Lewis R.A., Sumner A.J. The electrodiagnostic distinctions between chronic familial and acquired demyelinative neuropathies. Neurology 1982, 32(6):592-596.
18. Lewis R.A., Sumner A.J., Shy M.E. Electrophysiological features of inherited demyelinating neuropathies: a reappraisal in the era of molecular diagnosis. Muscle Nerve 2000, 23(10):1472-1487.
19. Ginsberg L., Malik O., Kenton A.R., et al. Coexistent hereditary and inflammatory neuropathy. Brain 2004, 127(1):193-202.
20. Dubourg O., Tardieu S., Birouk N., et al. The frequency of 17p11.2 duplication and Connexin 32 mutations in 282 Charcot-Marie-Tooth families in relation to the mode of inheritance and motor nerve conduction velocity. Neuromuscul Disord 2001, 11(5):458-463.
21. England J.D., Gronseth G.S., Franklin G., et al. Practice parameter: the evaluation of distal symmetric polyneuropathy: the role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PM R 2009, 1(1):5-13.
22. England J.D., Gronseth G.S., Franklin G., et al. Practice parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology 2009, 72(2):185-192.
23. Burgunder J.M., Schols L., Baets J., et al. EFNS guidelines for the molecular diagnosis of neurogenetic disorders: motoneuron, peripheral nerve and muscle disorders. Eur J Neurol 2011, 18(2):207-217.
24. Saporta A.S., Sottile S.L., Miller L.J., et al. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol 2011, 69(1):22-33.
25. Feely S.M., Laura M., Siskind C.E., et al. MFN2 mutations cause severe phenotypes in most patients with CMT2A. Neurology 2011, 76(20):1690-1696.
26. Krajewski K.M., Shy M.E. Genetic testing in neuromuscular disease. Neurol Clin 2004, 22(3):481-508. v.
27. Shy M.E., Chen L., Swan E.R., et al. Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology 2008, 70(5):378-383.
28. Shy M.E., Siskind C., Swan E.R., et al. CMT1X phenotypes represent loss of GJB1 gene function. Neurology 2007, 68(11):849-855.
29. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. American Society of Human Genetics Board of Directors, American College of Medical Genetics Board of Directors. Am J Hum Genet 1995, 57(5):1233-1241.
30. Kamholz J., Menichella D., Jani A., et al. Charcot-Marie-Tooth disease type 1: molecular pathogenesis to gene therapy. Brain 2000, 123(Pt 2):222-233.
31. Lupski J.R., de Oca-Luna R.M., Slaugenhaupt S., et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 1991, 66(2):219-232.
32. Raeymaekers P., Timmerman V., Nelis E., et al. Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). The HMSN Collaborative Research Group. Neuromuscul Disord 1991, 1(2):93-97.
33. Sheth S., Francies K., Siskind C.E., et al. Diabetes mellitus exacerbates motor and sensory impairment in CMT1A. J Peripher Nerv Syst 2008, 13(4):299-304.
34. Blair I.P., Nash J., Gordon M.J., et al. Prevalence and origin of de novo duplications in Charcot-Marie-Tooth disease type 1A: first report of a de novo duplication with a maternal origin. Am J Hum Genet 1996, 58(3):472-476.
35. Chance P.F., Alderson M.K., Leppig K.A., et al. DNA deletion associated with hereditary neuropathy with liability to pressure palsies. Cell 1993, 72(1):143-151.
36. Infante J., Garcia A., Combarros O., et al. Diagnostic strategy for familial and sporadic cases of neuropathy associated with 17p11.2 deletion. Muscle Nerve 2001, 24(9):1149-1155.
37. Stogbauer F., Young P., Kuhlenbaumer G., et al. Hereditary recurrent focal neuropathies: clinical and molecular features. Neurology 2000, 54(3):546-551.
38. Andersson P.B., Yuen E., Parko K., et al. Electrodiagnostic features of hereditary neuropathy with liability to pressure palsies. Neurology 2000, 54(1):40-44.
39. Li J., Krajewski K., Shy M.E., et al. Hereditary neuropathy with liability to pressure palsy: the electrophysiology fits the name. Neurology 2002, 58(12):1769-1773.
40. Hayasaka K., Himoro M., Sato W., et al. Charcot-Marie-Tooth neuropathy type 1B is associated with mutations of the myelin P0 gene. Nat Genet 1993, 5(1):31-34.
41. Street V.A., Bennett C.L., Goldy J.D., et al. Mutation of a putative protein degradation gene LITAF/SIMPLE in Charcot-Marie-Tooth disease 1C. Neurology 2003, 60(1):22-26.
42. Latour P., Gonnaud P.M., Ollagnon E., et al. SIMPLE mutation analysis in dominant demyelinating Charcot-Marie-Tooth disease: three novel mutations. J Peripher Nerv Syst 2006, 11(2):148-155.
43. Saifi G.M., Szigeti K., Wiszniewski W., et al. SIMPLE mutations in Charcot-Marie-Tooth disease and the potential role of its protein product in protein degradation. Hum Mutat 2005, 25(4):372-383.
44. Warner L.E., Mancias P., Butler I.J., et al. Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet 1998, 18(4):382-384.
45. Vandenberghe N., Upadhyaya M., Gatignol A., et al. Frequency of mutations in the early growth response 2 gene associated with peripheral demyelinating neuropathies. J Med Genet 2002, 39(12):e81.
46. Pareyson D., Taroni F., Botti S., et al. Cranial nerve involvement in CMT disease type 1 due to early growth response 2 gene mutation. Neurology 2000, 54(8):1696-1698.
47. Boerkoel C.F., Takashima H., Garcia C.A., et al. Charcot-Marie-Tooth disease and related neuropathies: mutation distribution and genotype-phenotype correlation. Ann Neurol 2002, 51(2):190-201.
48. Russo M., Laura M., Polke J.M., et al. Variable phenotypes are associated with PMP22 missense mutations. Neuromuscul Disord 2011, 21(2):106-114.
49. Zuchner S., Mersiyanova I.V., Muglia M., et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 2004, 36(5):449-451.
50. Verhoeven K., De Jonghe P., Coen K., et al. Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy. Am J Hum Genet 2003, 72(3):722-727.
51. Auer-Grumbach M., De Jonghe P., Wagner K., et al. Phenotype-genotype correlations in a CMT2B family with refined 3q13-q22 locus. Neurology 2000, 55(10):1552-1557.
52. De Jonghe P., Timmerman V., FitzPatrick D., et al. Mutilating neuropathic ulcerations in a chromosome 3q13-q22 linked Charcot-Marie-Tooth disease type 2B family. J Neurol Neurosurg Psychiatry 1997, 62(6):570-573.
53. Kwon J.M., Elliott J.L., Yee W.C., et al. Assignment of a second Charcot-Marie-Tooth type II locus to chromosome 3q. Am J Hum Genet 1995, 57(4):853-858.
54. Landoure G., Zdebik A.A., Martinez T.L., et al. Mutations in TRPV4 cause Charcot-Marie-Tooth disease type 2C. Nat Genet 2010, 42(2):170-174.
55. Chen D.H., Sul Y., Weiss M., et al. CMT2C with vocal cord paresis associated with short stature and mutations in the TRPV4 gene. Neurology 2010, 75(22):1968-1975.
56. Deng H.X., Klein C.J., Yan J., et al. Scapuloperoneal spinal muscular atrophy and CMT2C are allelic disorders caused by alterations in TRPV4. Nat Genet 2010, 42(2):165-169.
57. Dyck P.J., Litchy W.J., Minnerath S., et al. Hereditary motor and sensory neuropathy with diaphragm and vocal cord paresis. Ann Neurol 1994, 35(5):608-615.
58. Klein C.J., Cunningham J.M., Atkinson E.J., et al. The gene for HMSN2C maps to 12q23-24: a region of neuromuscular disorders. Neurology 2003, 60(7):1151-1156.
59. Antonellis A., Ellsworth R.E., Sambuughin N., et al. Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V. Am J Hum Genet 2003, 72(5):1293-1299.
60. Sivakumar K., Kyriakides T., Puls I., et al. Phenotypic spectrum of disorders associated with glycyl-tRNA synthetase mutations. Brain 2005, 128(Pt 10):2304-2314.
61. Mersiyanova I.V., Perepelov A.V., Polyakov A.V., et al. A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. Am J Hum Genet 2000, 67(1):37-46.
62. Georgiou D.M., Zidar J., Korosec M., et al. A novel NF-L mutation Pro22Ser is associated with CMT2 in a large Slovenian family. Neurogenetics 2002, 4(2):93-96.
63. Yoshihara T., Yamamoto M., Hattori N., et al. Identification of novel sequence variants in the neurofilament-light gene in a Japanese population: analysis of Charcot-Marie-Tooth disease patients and normal individuals. J Peripher Nerv Syst 2002, 7(4):221-224.
64. Jordanova A., De Jonghe P., Boerkoel C.F., et al. Mutations in the neurofilament light chain gene (NEFL) cause early onset severe Charcot-Marie-Tooth disease. Brain 2003, 126(Pt 3):590-597.
65. Perez-Olle R., Leung C.L., Liem R.K. Effects of Charcot-Marie-Tooth-linked mutations of the neurofilament light subunit on intermediate filament formation. J Cell Sci 2002, 115(Pt 24):4937-4946.
66. Evgrafov O.V., Mersiyanova I., Irobi J., et al. Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy. Nat Genet 2004, 36(6):602-606.
67. Chung K.W., Kim S.B., Cho S.Y., et al. Distal hereditary motor neuropathy in Korean patients with a small heat shock protein 27 mutation. Exp Mol Med 2008, 40(3):304-312.
68. Houlden H., Laura M., Wavrant-De Vrieze F., et al. Mutations in the HSP27 (HSPB1) gene cause dominant, recessive, and sporadic distal HMN/CMT type 2. Neurology 2008, 71(21):1660-1668.
69. Solla P., Vannelli A., Bolino A., et al. Heat shock protein 27 R127W mutation: evidence of a continuum between axonal Charcot-Marie-Tooth and distal hereditary motor neuropathy. J Neurol Neurosurg Psychiatry 2010, 81(9):958-962.
70. Tang B.S., Zhao G.H., Luo W., et al. Small heat-shock protein 22 mutated in autosomal dominant Charcot-Marie-Tooth disease type 2L. Hum Genet 2005, 116(3):222-224.
71. Irobi J., Van Impe K., Seeman P., et al. Hot-spot residue in small heat-shock protein 22 causes distal motor neuropathy. Nat Genet 2004, 36(6):597-601.
72. Tang B.S., Luo W., Xia K., et al. A new locus for autosomal dominant Charcot-Marie-Tooth disease type 2 (CMT2L) maps to chromosome 12q24. Hum Genet 2004, 114(6):527-533.
73. Baxter R.V., Ben Othmane K., Rochelle J.M., et al. Ganglioside-induced differentiation-associated protein-1 is mutant in Charcot-Marie-Tooth disease type 4A/8q21. Nat Genet 2002, 30(1):21-22.
74. Sivera R., Espinos C., Vilchez J.J., et al. Phenotypical features of the p.R120W mutation in the GDAP1 gene causing autosomal dominant Charcot-Marie-Tooth disease. J Peripher Nerv Syst 2010, 15(4):334-344.
75. Claramunt R., Pedrola L., Sevilla T., et al. Genetics of Charcot-Marie-Tooth disease type 4A: mutations, inheritance, phenotypic variability, and founder effect. J Med Genet 2005, 42(4):358-365.
76. Crimella C., Tonelli A., Airoldi G., et al. The GST domain of GDAP1 is a frequent target of mutations in the dominant form of axonal Charcot Marie Tooth type 2K. J Med Genet 2010, 47(10):712-716.
77. Senderek J., Bergmann C., Ramaekers V.T., et al. Mutations in the ganglioside-induced differentiation-associated protein-1 (GDAP1) gene in intermediate type autosomal recessive Charcot-Marie-Tooth neuropathy. Brain 2003, 126(Pt 3):642-649.
78. Nelis E., Erdem S., Van Den Bergh P.Y., et al. Mutations in GDAP1: autosomal recessive CMT with demyelination and axonopathy. Neurology 2002, 59(12):1865-1872.
79. Sevilla T., Cuesta A., Chumillas M.J., et al. Clinical, electrophysiological and morphological findings of Charcot-Marie-Tooth neuropathy with vocal cord palsy and mutations in the GDAP1 gene. Brain 2003, 126(Pt 9):2023-2033.
80. Boerkoel C.F., Takashima H., Nakagawa M., et al. CMT4A: identification of a Hispanic GDAP1 founder mutation. Ann Neurol 2003, 53(3):400-405.
81. Bolino A., Muglia M., Conforti F.L., et al. Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2. Nat Genet 2000, 25(1):17-19.
82. Houlden H., King R.H., Wood N.W., et al. Mutations in the 5' region of the myotubularin-related protein 2 (MTMR2) gene in autosomal recessive hereditary neuropathy with focally folded myelin. Brain 2001, 124(Pt 5):907-915.
83. Parman Y., Battaloglu E., Baris I., et al. Clinicopathological and genetic study of early-onset demyelinating neuropathy. Brain 2004, 127(Pt 11):2540-2550.
84. Tyson J., Ellis D., Fairbrother U., et al. Hereditary demyelinating neuropathy of infancy. A genetically complex syndrome. Brain 1997, 120(Pt 1):47-63.
85. Verny C., Ravise N., Leutenegger A.L., et al. Coincidence of two genetic forms of Charcot-Marie-Tooth disease in a single family. Neurology 2004, 63(8):1527-1529.
86. Senderek J., Bergmann C., Weber S., et al. Mutation of the SBF2 gene, encoding a novel member of the myotubularin family, in Charcot-Marie-Tooth neuropathy type 4B2/11p15. Hum Mol Genet 2003, 12(3):349-356.
87. Azzedine H., Bolino A., Taieb T., et al. Mutations in MTMR13, a new pseudophosphatase homologue of MTMR2 and Sbf1, in two families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease associated with early-onset glaucoma. Am J Hum Genet 2003, 72(5):1141-1153.
88. Senderek J., Bergmann C., Stendel C., et al. Mutations in a gene encoding a novel SH3/TPR domain protein cause autosomal recessive Charcot-Marie-Tooth type 4C neuropathy. Am J Hum Genet 2003, 73(5):1106-1119.
89. Gooding R., Colomer J., King R., et al. A novel Gypsy founder mutation, p.Arg1109X in the CMT4C gene, causes variable peripheral neuropathy phenotypes. J Med Genet 2005, 42(12):e69.
90. Colomer J., Gooding R., Angelicheva D., et al. Clinical spectrum of CMT4C disease in patients homozygous for the p.Arg1109X mutation in SH3TC2. Neuromuscul Disord 2006, 16(7):449-453.
91. Azzedine H., Ravise N., Verny C., et al. Spine deformities in Charcot-Marie-Tooth 4C caused by SH3TC2 gene mutations. Neurology 2006, 67(4):602-606.
92. Lassuthova P., Mazanec R., Vondracek P., et al. High frequency of SH3TC2 mutations in Czech HMSN I patients. Clin Genet 2011, 80(4):334-345.
93. Houlden H., Laura M., Ginsberg L., et al. The phenotype of Charcot-Marie-Tooth disease type 4C due to SH3TC2 mutations and possible predisposition to an inflammatory neuropathy. Neuromuscul Disord 2009, 19(4):264-269.
94. Boerkoel C.F., Takashima H., Stankiewicz P., et al. Periaxin mutations cause recessive Dejerine-Sottas neuropathy. Am J Hum Genet 2001, 68(2):325-333.
95. Guilbot A., Williams A., Ravise N., et al. A mutation in periaxin is responsible for CMT4F, an autosomal recessive form of Charcot-Marie-Tooth disease. Hum Mol Genet 2001, 10(4):415-421.
96. Marchesi C., Milani M., Morbin M., et al. Four novel cases of periaxin-related neuropathy and review of the literature. Neurology 2010, 75(20):1830-1838.
97. Kabzinska D., Drac H., Sherman D.L., et al. Charcot-Marie-Tooth type 4F disease caused by S399fsx410 mutation in the PRX gene. Neurology 2006, 66(5):745-747.
98. Chow C.Y., Zhang Y., Dowling J.J., et al. Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J. Nature 2007, 448(7149):68-72.
99. Zhang X., Chow C.Y., Sahenk Z., et al. Mutation of FIG4 causes a rapidly progressive, asymmetric neuronal degeneration. Brain 2008, 131(Pt 8):1990-2001.
100. Siskind C., Murphy S.M., Ovens R., et al. Phenotype expression in women with CMT1X. J Peripher Nerv Syst 2011, 16:102-107.
101. Siskind C., Feely S.M., Bernes S., et al. Persistent CNS dysfunction in a boy with CMT1X. J Neurol Sci 2009, 279(1-2):109-113.
102. Passage E., Norreel J.C., Noack-Fraissignes P., et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 2004, 10(4):396-401.
103. Verhamme C., de Haan R.J., Vermeulen M., et al. Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial. BMC Med 2009, 7:70.
104. Burns J., Ouvrier R.A., Yiu E.M., et al. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol 2009, 8(6):537-544.
105. Micallef J., Attarian S., Dubourg O., et al. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2009, 8(12):1103-1110.
106. Pareyson D., Reilly M.M., Schenone A., et al. Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol 2011, 10(4):320-328.
107. Sereda M.W., Meyer zu Hörste G., Suter U., et al. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 2003, 9(12):1533-1537.
108. Meyer zu Hörste G., Prukop T., Liebetanz D., et al. Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy. Ann Neurol 2007, 61(1):61-72.
109. d'Ydewalle C., Krishnan J., Chiheb D.M., et al. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat Med 2011, 17(8):968-974.
110. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126(4):663-676.
111. Dimos J.T., Rodolfa K.T., Niakan K.K., et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008, 321(5893):1218-1221.
112. Saporta M.A., Grskovic M., Dimos J.T. Induced pluripotent stem cells in the study of neurological diseases. Stem Cell Res Ther 2011, 2(5):37.
113. Lee G., Papapetrou E.P., Kim H., et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009, 461(7262):402-406.